Login Register Cart 0
Generic placeholder image

Current Pharmaceutical Design

Editor-in-Chief

ISSN (Print): 1381-6128
ISSN (Online): 1873-4286

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Mini-Review Article

A Case Study: Analysis of Patents on Coronaviruses and Covid-19 for Technological Assessment and Future Research

Author(s): Pankaj Musyuni, Geeta Aggarwal*, Manju Nagpal and Ramesh K. Goyal

Volume 27, Issue 3, 2021

Published on: 20 July, 2020

Page: [423 - 439] Pages: 17

DOI: 10.2174/1381612826666200720233947

Price: $65

Abstract

Background: Protecting intellectual property rights are important and particularly pertinent for inventions that are an outcome of rigorous research and development. While the grant of patents is subject to establishing novelty and inventive step, it further indicates the technological development and is helpful for researchers working in the same technical domain. The aim of the present research work is to map the existing work through an analysis of patent literature in the field of Coronaviruses (CoV), particularly COVID-19 (2019-nCoV). CoV is a large family of viruses known to cause illness in humans and animals, particularly known for causing respiratory infections, as evidenced in earlier times, such as in MERS i.e., Middle East Respiratory Syndrome; and SRS i.e., Severe Acute Respiratory Syndrome. A recently identified novel-coronavirus, known as COVID-19, has caused pandemic situations across the globe.

Objective: To expand the analysis of patents related to CoV and 2019-nCoV, an evaluation has been conducted by patenting trends of particular strains of identified CoV diseases by present legal status, main concerned countries via the earliest priority years and its assignee types and inventors of identified relevant patents. The global patent documents were analyzed to check the scope of claims along with focuses and trends of the published patent documents for the entire CoV family, including 2019-nCoV through the present landscape.

Methods: To extract the results, the Derwent Innovation database was used by a combination of different keystrings. Approximately 3800 patents were obtained and further scrutinized and analyzed. The present write-up also discusses the recent progress of patent applications in a period of the year 2010 to 2020 (present) along with the recent developments in India for the treatment options for CoV and 2019-nCoV.

Results: Present analysis showed that key areas of the inventions were the vaccines and diagnostic kits apart from the composition for the treatment of CoV. It was also observed that no specific vaccine treatments are available for the treatment of 2019-nCov; however, developing novel chemical or biological drugs and kits for early diagnosis, prevention, and disease management is the primary governing topic among the patented inventions. The present study also indicates potential research opportunities for the future, particularly to combat 2019-nCoV.

Conclusion: The present paper analyzes the existing patents in the field of Coronaviruses and 2019-nCoV and suggests a way forward for the effective contribution in this upcoming research area. From the trend analysis, an increase in the filing of the overall trend of patent families was observed for a period of 2010 to the current year. This multifaceted analysis of identified patent literature provides an understanding of the focuses on present ongoing research and a grey area in terms of the trends of technological innovations in disease management in patients with CoV and 2019-nCoV. Furthermore, the findings and outcome of the present study offer insights for the proposed research and innovation opportunities and provide actionable information in order to facilitate policymakers, academia, research-driven institutes and also investors to make better decisions regarding programmed steps for research and development for the diagnosis, treatment and taking preventive measures for CoV and 2019-nCoV. The present article also emphasizes the need for future development and the role of academia and collaboration with industry for speedy research with a rationale.

Keywords: Coronaviruses (CoV), COVID-19 (2019-nCoV), patents, patent analysis, IPC, research evaluation, academia, technology assessment.

« Previous Next »
[1]
Woo PC, Huang Y, Lau SK, Yuen KY. Coronavirus genomics and bioinformatics analysis. Viruses 2010; 2(8): 1804-20.
[http://dx.doi.org/10.3390/v2081803] [PMID: 21994708]
[2]
Drexler JF, Gloza-Rausch F, Glende J, et al. Genomic characterization of severe acute respiratory syndrome-related coronavirus in European bats and classification of coronaviruses based on partial RNA-dependent RNA polymerase gene sequences. J Virol 2010; 84(21): 11336-49.
[http://dx.doi.org/10.1128/JVI.00650-10] [PMID: 20686038]
[3]
Yin Y, Wunderink RG. MERS, SARS and other coronaviruses as causes of pneumonia. Respirology 2018; 23(2): 130-7.
[http://dx.doi.org/10.1111/resp.13196] [PMID: 29052924]
[4]
Peiris JSM, Lai ST, Poon LL, et al. Coronavirus as a possible cause of severe acute respiratory syndrome. Lancet 2003; 361(9366): 1319-25.
[http://dx.doi.org/10.1016/S0140-6736(03)13077-2] [PMID: 12711465]
[5]
Zaki AM, van Boheemen S, Bestebroer TM, Osterhaus AD, Fouchier RA. Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. N Engl J Med 2012; 367(19): 1814-20.
[http://dx.doi.org/10.1056/NEJMoa1211721] [PMID: 23075143]
[6]
Dietz L, Horve PF, Coil DA, Fretz M, Eisen JA, Van Den Wymelenberg K. 2019 novel coronavirus (COVID-19) pandemic: built environment considerations to reduce transmission. mSystems 2020; 5(2): e00245-20.
[http://dx.doi.org/10.1128/mSystems.00245-20] [PMID: 32265315]
[7]
Paules CI, Marston HD, Fauci AS. Coronavirus infections more than just the common cold. JAMA 2020; 323(8): 707-8.
[http://dx.doi.org/10.1001/jama.2020.0757] [PMID: 31971553]
[8]
Schoeman D, Fielding BC. Coronavirus envelope protein: Current knowledge. Virol J 2019; 16(1): 69.
[http://dx.doi.org/10.1186/s12985-019-1182-0] [PMID: 31133031]
[9]
Chen Z, Zhang W, Lu Y, et al. From SARS-CoV to Wuhan 2019-nCoV Outbreak: Similarity of early epidemic and prediction of future trends. Cell Press 2020.
[10]
Cui J, Li F, Shi ZL. Origin and evolution of pathogenic coronaviruses. Nat Rev Microbiol 2019; 17(3): 181-92.
[http://dx.doi.org/10.1038/s41579-018-0118-9] [PMID: 30531947]
[11]
Seven days in medicine: 8-14 Jan 2020. BMJ 2020; 16.
[http://dx.doi.org/10.1136/bmj.m132]
[12]
Hui D S. The continuing 2019-nCoV epidemic threat of novel coronaviruses to global health - The latest 2019 novel coronavirus outbreak in Wuhan, China. International journal of infectious diseases: IJID: Official publication of the international society for infectious diseases 2020; 91: 264-6..
[13]
Imperial College London. Report 2: Estimating the potential total number of novel coronavirus cases in Wuhan City, China. 2020. Available from:. https://www.imperial.ac.uk/mrc-globalinfectious disease- analysis/news-wuhan-coronavirus
[14]
Jun Zheng SARS-CoV-2: An emerging coronavirus that causes a global threat. International journal of biological sciences 2020; 16(10): 1678-85.
[15]
Justyna Miłek, Katarzyna Blicharz-Domańska. Coronaviruses in avian species - review with focus on epidemiology and diagnosis in wild birds. J Veterinary Res 2018; 62(3): 249-55.
[16]
Kahn JS, McIntosh K. History and recent advances in coronavirus discovery. Pediatr Infect Dis J 2005; 24(11): S223-7.
[http://dx.doi.org/10.1097/01.inf.0000188166.17324.60] [PMID: 16378050]
[17]
What to know about coronaviruses. Available from:. https://www.medicalnewstoday.com/articles/256521#covid-19
[18]
Geller C, Varbanov M, Duval RE. Human coronaviruses: Insights into environmental resistance and its influence on the development of new antiseptic strategies. Viruses 2012; 4(11): 3044-68.
[http://dx.doi.org/10.3390/v4113044] [PMID: 23202515]
[19]
Cheng VC, Chan JF, To KK, Yuen KY. Clinical management and infection control of SARS: Lessons learned. Antiviral Res 2013; 100(2): 407-19.
[http://dx.doi.org/10.1016/j.antiviral.2013.08.016] [PMID: 23994190]
[20]
Berry M, Gamieldien J, Fielding BC. Identification of new respiratory viruses in the new millennium. Viruses 2015; 7(3): 996-1019.
[http://dx.doi.org/10.3390/v7030996] [PMID: 25757061]
[21]
Skariyachan S, Challapilli SB, Packirisamy S, Kumargowda ST, Sridhar VS. Recent aspects on the pathogenesis mechanism, animal models and novel therapeutic interventions for Middle East respiratory syndrome coronavirus infections. Front Microbiol 2019; 10: 569.
[http://dx.doi.org/10.3389/fmicb.2019.00569] [PMID: 30984127]
[22]
Bonilla-Aldana DK, Holguin-Rivera Y, Cortes-Bonilla I, et al. Coronavirus infections reported by ProMED, February 2000-January 2020. Travel Med Infect Dis 2020; 35101575
[http://dx.doi.org/10.1016/j.tmaid.2020.101575] [PMID: 32036011]
[23]
Song Z, Xu Y, Bao L, et al. From SARS to MERS, thrusting coronaviruses into the spotlight. Viruses 2019; 11(1)E59
[http://dx.doi.org/10.3390/v11010059] [PMID: 30646565]
[24]
World Health Organization Available from: . https://www.who. int/china/news/detail/09-01-2020-who-statement-regarding-cluster-of-pneumonia-cases-in-wuhan-china
[25]
Zhu N, Zhang D, Wang W, et al. A Novel Coronavirus from Patients with Pneumonia in China, 2019. N Engl J Med 2020; 382(8): 727-33.
[http://dx.doi.org/10.1056/NEJMoa2001017] [PMID: 31978945]
[26]
Lu R, Zhao X, Li J, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: Implications for virus origins and receptor binding. Lancet 2020; 395(10224): 565-74.
[http://dx.doi.org/10.1016/S0140-6736(20)30251-8] [PMID: 32007145]
[27]
Hu B, Zeng L-P, Yang X-L, et al. Discovery of a rich gene pool of bat SARS-related coronaviruses provides new insights into the origin of SARS coronavirus. PLoS Pathog 2017; 13(11)e1006698
[http://dx.doi.org/10.1371/journal.ppat.1006698] [PMID: 29190287]
[28]
Xu J, Zhao S, Teng T, et al. Systematic comparison of two animal-to-human transmitted human coronaviruses: SARS-CoV-2 and SARS-CoV. Viruses 2020; 12(2): 244.
[http://dx.doi.org/10.3390/v12020244] [PMID: 32098422]
[29]
Luk HKH, Li X, Fung J, Lau SKP, Woo PCY. Molecular epidemiology, evolution and phylogeny of SARS coronavirus. Infect Genet Evol 2019; 71: 21-30.
[http://dx.doi.org/10.1016/j.meegid.2019.03.001] [PMID: 30844511]
[30]
Coronavirinae in viralzone. Available from: . https://viralzone. expasy.org/785
[31]
Prajapat M, Sarma P, Shekhar N, et al. Drug targets for corona virus: A systematic review. Indian J Pharmacol 2020; 52(1): 56-65.
[http://dx.doi.org/10.4103/ijp.IJP_115_20] [PMID: 32201449]
[32]
Kadioglu O, Saeed M, Johannes Greten H, Efferth T. Identification of novel compounds against three targets of SARS CoV-2 coronavirus by combined virtual screening and supervised machine learning. Bull World Health Organ 2020; (March): 21.
[33]
Singhal T. A review of coronavirus disease-2019 (COVID-19). Indian J Pediatr 2020; 87(4): 281-6.
[http://dx.doi.org/10.1007/s12098-020-03263-6] [PMID: 32166607]
[34]
Cheng VCC, Lau SKP, Woo PCY, Yuen KY. Severe acute respiratory syndrome coronavirus as an agent of emerging and reemerging infection. Clin Microbiol Rev 2007; 20(4): 660-94.
[http://dx.doi.org/10.1128/CMR.00023-07] [PMID: 17934078]
[35]
Fung TS, Liu DX. Human coronavirus: Host-pathogen interaction. Annu Rev Microbiol 2019; 73: 529-57.
[http://dx.doi.org/10.1146/annurev-micro-020518-115759] [PMID: 31226023]
[36]
Yang J, Zheng Y, Gou X, et al. Prevalence of comorbidities and its effects in coronavirus disease 2019 patients: A systematic review and meta-analysis. Int J Infect Dis 2020; 94: 91-5.
[http://dx.doi.org/10.1016/j.ijid.2020.03.017] [PMID: 32173574]
[37]
Hassan SA, Sheikh FN, Jamal S, Ezeh JK, Akhtar A. Coronavirus (COVID-19): A review of clinical features, diagnosis, and treatment. Cureus 2020; 12(3)e7355
[http://dx.doi.org/10.7759/cureus.7355] [PMID: 32328367]
[38]
World Health Organization (WHO). Q & A on coronaviruses (COVID-19). Available from:. www.who.int/news-room/q-a-detail/q-a-coronaviruses
[39]
Respiratory hygiene/cough etiquette in healthcare settings, centers for disease control and prevention. Available from:. https://www. cdc.gov/flu/professionals/infectioncontrol/resphygiene.htm
[40]
Patents Google; P. 2-Substd-tetrahydrodicycloalk (e,g) isoindolins - useful against rhino-and corona virus infections. Available from. https://patents.google.com/patent/FR2263769A1/en?oq=FR2263769A1
[41]
World Intellectual Property Organization (WIPO). International patent classification: Frequently asked questions. Available from:. https://www.wipo.int/classifications/ipc/en/faq/
[42]
International Patent Classification (IPC), World Intellectual Property Organization (WIPO). Available from: . https://www.wipo.int/classifications/ipc/en/
[43]
https://www.wipo.int/classifications/ipc/ipcpub/?notion=scheme&version
[44]
Guidelines for preparing patent landscape reports, by anthony trippe, patinformatics, LLC. Available from:. https://www.wipo.int/edocs/pubdocs/en/wipo_pub_946.pdf
[45]
World Health Organization (WHO). Available from: . https://www. who.int/blueprint/priority-diseases/key-action/Novel_Coronavirus_ Landscape_nCoV_11April2020.PDF?ua=1
[46]
Patents Google Fluorescent quantitative PCR detection method for human coronavirus and respiratory syncytial virus and application thereof. Available from:. https://patents.google.com/patent/CN110724764A/en?oq=CN201911011029A
[47]
Patents Google; Broad-spectrum antivirals against 3c or 3c-like proteases of picornavirus-like supercluster: picornaviruses, caliciviruses and coronaviruses. Available from: . https://patents.google. com/patent/CA2850003A1/en?oq=CA2850003A
[48]
Patents Google The quadruple fluorescence quantitative detection kit of four kinds of human corona virus is detected simultaneously. Available from: . https://patents.google.com/patent/CN110144422A/en?oq=CN201910520231A
[49]
Patents Google Suppress polypeptide and its application of human coronary virus’s infection wide spectrum. Available from:. https://patents.google.com/patent/CN107022008A/en?oq=CN201610070216A
[50]
Patents Google; Macrocyclic and peptidomimetic compounds as broad-spectrum antivirals against 3C or 3C-like proteases of picornaviruses, caliciviruses and coronaviruses. Available from:. https://patents.google.com/patent/US9309284B2/en?oq=US9309284B2
[51]
Patents Google Compounds and methods for treating respiratory diseases. Available from: . https://patents.google.com/patent/US20110269834A1/en?oq=US20110269834
[52]
Patents Google Booklet for training rapid reading skill, capable of educating english and strengthening concentration to readers. Available from: . https://patents.google.com/patent/KR20200035379A/en?oq=KR20200032050A
[53]
Indian Patent Office. Available from:. http://www.ipindia.nic.in/index.htm http://ipindiaservices.gov.in/PatentSearch/PatentSearch//ViewApplicationStatus
[54]
Patents Google Prescription for treating pneumonia infected by novel coronavirus and application thereof. Available from: . https://patents.google.com/patent/CN110870402A/en?oq=CN110870402A
[55]
Wang M. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. 2019. Available from:. https://www.nature.com/articles/s41422-020-0282-0
[56]
Dong L, Hu S, Gao J. Discovering drugs to treat coronavirus disease 2019 (COVID-19). Drug Discov Ther 2020; 14(1): 58-60.
[http://dx.doi.org/10.5582/ddt.2020.01012] [PMID: 32147628]
[57]
Rabby MI. Current Drugs with Potential for Treatment of COVID-19: A literature review: drugs for the treatment process of COVID-19. J Pharm Pharm Sci 2020; 23: 58-64.
[http://dx.doi.org/10.18433/jpps31002]
[58]
Section 107 A of the Indian Patents Act. Available from:. https://indiankanoon.org/doc/151051886/
[59]
United States Patent and Trademark Office. Available from:. https://www.uspto.gov/web/offices/pac/mpep/consolidated_laws.pdf
[60]
World Health Organization (WHO) Available from:. https://www.who.int/blueprint/priority-diseases/key-action/novel-coronavirus/en/
[61]
The Central Drugs Standard Control Organisation (CDSCO) Available from:. https://cdsco.gov.in/opencms/opencms/en/Latest-Public-Notices/
[62]
US Food and Drug Administration Available from:. https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-provides-more-regulatory-relief-during-outbreak-continues-help
[63]
US Food and Drug Administration Available from:. https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-continues-accelerate-development-novel-therapies-covid-19
[64]
Serum Institute of India Pvt Available from:. https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/serum-institute-to-be-ready-with-coronavirus-vaccine-by-2022/articleshow/74212495.cms?from=mdr
[65]
Serum Institute of India Pvt Ltd Available from:. https://www.cnbctv18.com/healthcare/serum-institute-to-go-for-human-trials-for-covid-19-vaccine-by-year-end-says-adar-poonawala-5606211.htm
[66]
Serum Institute of India Pvt Ltd Available from:. https://health.economictimes.indiatimes.com/news/diagnostics/mylab-partners-with-serum-indias-poonawalla-apgs-pawar-to-scale-up-production-of-covid-19-test-kits/74944684
[67]
Council of Indian Institutes of Technology Available from:. https://iitsystem.ac.in/?q=covid19/summary
[68]
Press Information Bureau Government of India, Ministry of Science & Technology Available from:. https://pib.gov.in/newsite/
[69]
Available from. https://www.ibef.org/news/bharat-biotech-in-tieup-to-develop-a-covid-vaccine
[70]
Available from. https://www.sctimst.ac.in/COVID-19/
[71]
Prasar V. An autonomous organisation under Department of Science and Technology Available from: https://vigyanprasar.gov.in/wp-content/uploads/Coating-developed-by-JNCASR-may-prevent-transmission-of-infection-apr2020.pdf
[72]
Available from. https://ahmedabadmirror.indiatimes.com/ahmedabad/cover-story/in-lockdown-country-start-ups-take-lead-in-battle-against-covid-19/articleshow/74903153.cms
[73]
Pad Care Labs. Available from: . https://padcarelabs.com/covid19/
[74]
The Centre for cellular and molecular platforms. Available from:. http://www.ccamp.res.in/
[75]
Bione. Available from:. https://www.bione.in/
[76]
Indian Institute of Technology. Roorkee. Available from:. https://www.iitr.ac.in/Main/pages/Media_Mention.html
[77]
Available from . https://economictimes.indiatimes.com/news/economy/policy/beyond-contact-tracing-aarogya-setu-may-find-use-in-policy-inputs/articleshow/75078678.cms
[78]
Mylab discovery solutions. Available from:. https://mylabdiscoverysolutions.com/first-made-in-india-covid-19-tests-kit-by-mylab/
[79]
Sekhar Talluri. Virtual Screening based prediction of potential drugs for COVID-19. Available from: https://doi.org/ 87 10.20944/preprints202002.0418.v2.
[80]
Press Information Bureau. Government of India, Ministry of Science & Technology Available from. https://pib.gov.in/newsite/PrintRelease.aspx?relid=201036

Rights & Permissions Print Cite
Article Metrics
56
2
World Health Day
© 2024 Bentham Science Publishers | Privacy Policy